6
Tetrahedron
ACCEPTED MANUSCRIPT
Activity AA10R automatic polarimeter. TLC was performed on
1H), 4.69 (d, J = 11.7 Hz, 1H), 4.62 (d, J = 11.9 Hz, 1H), 4.55 (d,
glass plates coated with Silica Gel GF254 (Merck). Column
chromatography was performed on Silica Gel H60 (Haiyang
Chemical Factory, Qingdao, Shandong, China). Solvents were
purified by standard procedures.
J = 12.2 Hz, 1H), 4.47 (dd, J = 12.1, 4.2 Hz, 2H), 4.32 (dd, J =
3.5, 2.5 Hz, 1H, H-6), 4.26 (ddd, J = 18.0, 9.8, 1.6 Hz, 1H, H-3’),
4.02 (dd, J = 7.0, 3.9 Hz, 1H, H-4), 3.85 (t, J = 3.8 Hz, 1H, H-5),
2.57 (ddd, J = Hz, 1H, H-3a); 13C NMR (101 MHz, CDCl3) δ
138.32, 138.18, 137.88, 128.64, 128.49, 128.43, 128.01, 127.90,
127.75, 127.65, 127.63, 127.52, 96.07, 82.33, 81.35, 79.16,
78.38, 77.55, 77.23, 76.91, 72.62, 72.35, 72.23, 34.61; HRMS
(ES) m/z calcd for C27H29N2O3, [M+H]+: 429.2178, found:
429.2189.
5.2. General procedure for the preparation of polyhydroxy
bicyclic diazene 3a-3g
Procedure Aꢁ
To a solution of iodide (1 mmol) in 95% EtOH (10 mL)
activated Zn (650 mg, 10 mmol) was added and the mixture was
refluxed with vigorous stirring complete disappearance of iodide
(2 h). The mixture was cooled to room temperature, the solids
were filtered off and the solvent was evaporated. Then the
residue was dissolved into DCM, then washed with saturated
aqueous Na2S2O3, dried (Na2SO4), filtered, and concentrated
under reduced pressure to give pure aldehyde.
5.2.3. (3aR,4R,5S,6R,6aS)-4,5,6-tris(benzyloxy)-
3,3a,4,5,6,6a-hexahydrocyclopenta[c]pyrazole 3c
25
1
Syrup. [α]D +32.0 (c 1.00, CHCl3); H NMR (400 MHz,
CDCl3) δ 7.69 – 7.07 (m, 15H), 4.99 (ddt, J = 8.8, 3.3, 1.8 Hz,
1H, H-3), 4.89 (dt, J = 18.6, 3.4 Hz, 1H, H-6a), 4.83 (d, J = 12.0
Hz, 1H), 4.77 (d, J = 12.0 Hz, 1H), 4.60 (d, J = 11.9 Hz, 1H),
4.56 (d, J = 12.1 Hz, 1H), 4.52 (d, J = 12.1 Hz, 1H), 4.47 (d, J =
11.9 Hz, 1H), 4.32 – 4.23 (m, 2H, H-6, H-3’), 4.20 (t, J = 7.9 Hz,
1H, H-4), 3.19 (dd, J = 7.9, 4.4 Hz, 1H, H-5), 2.66 (ddd, J = 12.6,
9.5, 3.6 Hz, 1H, H-3a); 13C NMR (101 MHz, CDCl3) δ 138.22,
138.03, 128.63, 128.57, 128.50, 128.16, 128.03, 127.89, 127.81,
127.73, 94.67, 82.20, 81.34, 77.90, 77.55, 77.23, 76.91, 76.54,
72.72, 72.57, 72.46, 32.87; HRMS (ES) m/z calcd for
C27H29N2O3, [M+H]+: 429.2178, found: 429.2191.
The hex-5-enals 1 (0.5mmol) and tosylhydrazine (1.05 equiv,
0.525 mmol) were stirred in MeOH (2 mL) at rt overnight.
The MeOH was removed under reduced pressure, the crude
hydrazone was redissolved in toluene (2 mL), K2CO3 (6 equiv, 3
mmol) was added and the reaction mixture was heated in a sealed
vial at 120°C (oil bath) for 12 h. After cooling to rt, the reaction
mixture was partitioned between CH2Cl2 and, sequentially, water
and brine. The combined organic extracts were dried (Na2SO4)
and concentrated. The residue was chromatographed to yield 3.
5.2.4. (3aS,4S,5S,6S,6aR)-4,5-O-isopropylidene-6-
benzyloxy-3,3a,4,5,6,6a-
hexahydrocyclopenta[c]pyrazole 3d
25
1
Syrup. [α]D +32.0 (c 1.00, CHCl3); H NMR (400 MHz,
CDCl3) δ 7.74 – 6.96 (m, 5H), 5.18 (d, J = 17.4 Hz, 1H, H-3),
4.81 (d, J = 7.9 Hz, 1H, H-6a), 4.75 (d, J = 15.7 Hz, 3H, H-6, -
CH2Ph), 4.62 (d, J = 5.7 Hz, 1H, H-5), 4.60 – 4.54 (m, 1H, H-4),
4.06 (ddd, J = 17.4, 8.3, 2.7 Hz, 1H, H-3), 2.72 (q, J = 7.5 Hz, 1H,
H-3a), 1.22 (s, 6H); 13C NMR (101 MHz, CDCl3) δ 137.57,
128.93, 128.77, 128.25, 128.14, 128.05, 127.97, 111.44, 100.14,
85.93, 85.79, 83.75, 80.74, 80.58, 77.55, 77.23, 76.91, 72.17,
37.87, 26.23, 24.54; HRMS (ES) m/z calcd for C16H21N2O3,
[M+H]+: 289.1552, found: 289.1559.
Procedure Bꢁ
To a solution of iodide (1 mmol) in 95% EtOH (10 mL)
activated Zn (650 mg, 10 mmol) was added and the mixture was
refluxed with vigorous stirring complete disappearance of iodide
(2 h). The mixture was cooled to room temperature, the solids
were filtered off and the solvent was evaporated. Then the
residue was dissolved into DCM, then washed with saturated
aqueous Na2S2O3, dried (Na2SO4), filtered, and concentrated
under reduced pressure to give pure aldehyde.
Hex-5-enals 1 (0.5mmol) and tosylhydrazine (1.05 equiv,
0.525 mmol) were stirred in toluene with Et3N (5-10 equiv) at rt
for 2h.
5.2.5. (3aR,4R,5S,6R,6aS)-4-benzyloxy-5,6-O-
isopropylidene-3,3a,4,5,6,6a-
hexahydrocyclopenta[c]pyrazole 3e
25
1
Syrup. [α]D +32.0 (c 1.00, CHCl3); H NMR (400 MHz,
CDCl3) δ 7.50 – 7.14 (m, 5H), 5.18 (d, J = 5.3 Hz, 1H, H-6), 4.98
(dt, J = 17.5, 2.0 Hz, 1H, H-3), 4.82 (d, J = 8.2 Hz, 1H, H-6a),
4.60 (d, J = 12.2 Hz, 1H), 4.44 (dd, J = 5.3, 1.7 Hz, 1H, H-5),
4.40 (d, J = 12.2 Hz, 1H), 4.06 (ddd, J = 17.5, 8.4, 2.4 Hz, 1H, H-
3), 3.88 (dd, J = 6.7, 1.8 Hz, 1H, H-4), 2.88 (td, J = 8.4, 1.8 Hz,
1H, H-3a), 1.48 (s, 3H), 1.36 (s, 3H); 13C NMR (101 MHz,
CDCl3) δ 137.67, 128.61, 127.93, 127.56, 111.78, 99.32, 83.77,
82.94, 81.39, 77.55, 77.23, 76.91, 72.16, 38.06, 27.48, 25.30;
HRMS (ES) m/z calcd for C16H21N2O3, [M+H]+: 289.1552,
found: 289.1560.
To the reaction mixture, K2CO3 (6 equiv, 3 mmol) was added,
and then was heated in a sealed vial at 120°C (oil bath) for 12 h.
After cooling to room temperature, the reaction mixture was
filtered and concentrated. The residue was chromatographed to
yield 3.
5.2.1. (3aS,4R,5S,6S,6aR)-4,5,6-tris(benzyloxy)-
3,3a,4,5,6,6a-hexahydrocyclopenta[c]pyrazole 3a
White solid. [α]D25 +32.0 (c 1.00, CHCl3) 1H NMR (400 MHz,
CDCl3) δ 7.53 – 7.15 (m, 15H), 5.05 (d, J = 11.8 Hz, 1H), 4.91 –
4.85 (m, 1H, H-6a), 4.85 – 4.49 (m, 6H), 4.45 (dt, J = 18.2, 2.8
Hz, 1H, H-3), 4.36 (ddd, J = 18.2, 8.9, 2.2 Hz, 1H, H-3’), 4.05 (t,
J = 7.5 Hz, 1H, H-5), 3.95 – 3.89 (m, 1H, H-6), 3.26 (t, J = 7.5
Hz, 1H, H-4), 2.43 (ddd, J = 12.6, 10.3, 3.3 Hz, 1H, H-3a); 13C
NMR (101 MHz, CDCl3) δ 138.36, 138.08, 137.81, 128.64,
128.62, 128.50, 128.17, 128.03, 127.99, 127.88, 127.83, 127.77,
127.72, 95.23, 86.58, 86.03, 83.11, 82.39, 77.55, 77.23, 76.91,
72.75, 72.38, 72.30, 36.56; HRMS (ES) m/z calcd for
C27H29N2O3, [M+H]+: 429.2178, found: 429.2191.
5.2.6. (3aS,4R,5S,6R,6aS)-4-benzyloxy-5,6-O-
isopropylidene-1,3a,4,5,6,6a-
hexahydrocyclopenta[c]pyrazole 4e
1
Syrup. H NMR (400 MHz, CDCl3) δ 7.38 – 7.12 (m, 7H),
6.73 (d, J = 1.2 Hz, 1H), 4.66 (d, J = 12.1 Hz, 1H), 4.48 (d, J =
12.1 Hz, 1H), 4.42 (dd, J = 6.0, 4.3 Hz, 1H), 4.32 (d, J = 6.2 Hz,
1H), 4.10 (dd, J = 7.5, 4.2 Hz, 1H), 3.98 (d, J = 9.7 Hz, 1H), 3.71
(ddd, J = 9.4, 1.4, 0.7 Hz, 1H), 1.37 (s, 4H), 1.22 (s, 4H); 13C
NMR (101 MHz, CDCl3) δ 143.45, 137.94, 128.56, 127.93,
127.87, 111.97, 87.40, 85.74, 85.68, 77.55, 77.23, 76.91, 72.14,
66.19, 55.07, 27.49, 25.24. HRMS (ES) m/z calcd for
C16H21N2O3, [M+H]+: 289.1552, found: 289.1560.
5.2.2. (3aS,4R,5S,6S,6aR)-4,5,6-tris(benzyloxy)-
3,3a,4,5,6,6a-hexahydrocyclopenta[c]pyrazole 3b
25
1
Syrup. [α]D +32.0 (c 1.00, CHCl3); H NMR (400 MHz,
CDCl3) δ 7.54 – 7.13 (m, 15H), 4.99 (dt, J = 18.0, 3.3 Hz, 1H, H-
3), 4.92 (dd, J = 9.0, 1.5 Hz, 1H, H-6a), 4.83 (d, J = 11.7 Hz,